


50 years of contribution

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION



■ **Circulation Electronic Pages**

Correspondence ★e180-e183
 Cardiovascular News ★

■ **Editorial**

Provisional vs Routine Stenting
H. Vernon Anderson, MD; Blase A. Carabello, MD.....2910

■ **Brief Rapid Communications**

γ-Radiation for In-Stent Restenosis
Gary S. Mintz, MD, et al.....2915
 CD4⁺ T Cells Aggravate Atherosclerosis
Xinghua Zhou, MD, PhD, et al.....2919

■ **Clinical Investigation and Reports**

Economics of GP IIb/IIIa Receptor Blockade During PTCA
A. Michael Lincoff, MD, et al.....2923
 Comparison of Primary Stenting and Provisional Angioplasty
Patrick W. Serruys, MD, et al.....2930
 Doppler-Guided PTCA vs Elective Stenting
Carlo Di Mario, MD, PhD, et al.....2938
 Percutaneous Coronary Intervention in the Current Era
David O. Williams, MD, et al.....2945
 Eptifibatid and Coronary Artery Bypass Surgery
Steven P. Marso, MD, et al.....2952
 Collateral Circulation in Chronic Coronary Occlusions
Gerald S. Werner, MD, et al.....3023

PCI in Patients With Renal Failure

Mark H. Rubenstein, MD, et al.....2966

Morbidity and Mortality in Dialysis Patients Having CABG

Jean Y. Liu, MD, et al.....2973

Chagas' Disease in Patients Having Cardiac Surgery

David A. Leiby, PhD, et al.....2978

■ **Basic Science Reports**

Acute and Chronic Effects of Estrogen Following MI
Paula J.W. Smith, PhD, et al.....2983
 Estrogen and Human Cytomegalovirus
Edith Speir, MS, et al.....2990
 Sildenafil and Coronary Blood Flow
Jay H. Traverse, MD, et al.....2997
 Chemokine and NO Production by Cardiomyocytes
Fabiana S. Machado, MS, et al.....3003
 Marinobufagenin and Ouabain in Salt-Loaded Dahl Rats
Olga V. Fedorova, PhD, et al.....3009
 Endotoxin-Induced Mortality in HO-1 Null Mice
Philippe Wiesel, MD, et al.....3015

■ **Images in Cardiovascular Medicine**

Granulomatous Aortitis Presenting as AMI
Michael H. Goldman, MD, et al.....3023

This material was copied at the NLM and may be subject to US Copyright Law

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Volume 102 ■ Number 24
December 12, 2000

Circulation Electronic Pages

Correspondence

- Fen/Phen and Valvular Heart Disease: The Final Link Has Now Been Established**
Letter *Tsung O. Cheng, MD* **Web Site Feature** ★e180
- The Naming of Jugular Venous Valves**
Letter *Jeffrey Fisher, MD*
Response *Charles F. Babbs, MD, PhD* **Web Site Feature** ★e181
- Ventilatory and Heart Rate Responses to Exercise: Better Predictors of Heart Failure Mortality Than Peak Exercise Oxygen Consumption**
Letter *Guy A. MacGowan, MD, FACC; Srinivas Murali, MD, FACC*
Response *Michael S. Lauer, MD; Mark Robbins, MD; Fredric Pashkow, MD; Kathy Hoercher, RN; Claire E. Snader, MA; James B. Young, MD; Gary Francis, MD* **Web Site Feature** ★e182
- Smoking and Aldosterone Synthase Polymorphism**
Letter *Pitt O. Lim, MD*
Response *Aarno Hautanen, MD; M. Mänttari, MD; Markku Kupari, MD; V. Manninen, MD; Petri Toivanen, PhD; Leena Tenkanen, PhD; Kathleen M. Kayes, PhD; Scott Rosenfeld, BS; Perrin C. White, MD* **Web Site Feature** ★ e183

Editorial

- Provisional Versus Routine Stenting: Routine Stenting Is Here To Stay**
H. Vernon Anderson, MD; Blase A. Carabello, MD 2910

Brief Rapid Communications

- Effect of Intracoronary γ -Radiation Therapy on In-Stent Restenosis: An Intravascular Ultrasound Analysis from the Gamma-1 Study**
Gary S. Mintz, MD; Neil J. Weissman, MD; Paul S. Teirstein, MD; Steven G. Ellis, MD; Ron Waksman, MD; Robert J. Russo, MD; Issam Moussa, MD; Prabhaker Tripuraneni, MD; Shrish Jani, MD; Yoshio Kobayashi, MD; Joseph A. Giorgianni, BA; Chrysoula Pappas, MD; Richard A. Kuntz, MD; Jeffrey Moses, MD; Martin B. Leon, MD 2915
- Transfer of CD4⁺ T Cells Aggravates Atherosclerosis in Immunodeficient Apolipoprotein E Knockout Mice**
Xinghua Zhou, MD, PhD; Antonino Nicoletti, PhD; Rima Elhage, PhD; Göran K. Hansson, MD, PhD 2919

Clinical Investigation and Reports*

- Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization: Results From the EPILOG Randomized Trial**
A. Michael Lincoff, MD; Daniel B. Mark, MD, MPH; James E. Tcheng, MD; Robert M. Califf, MD; Mohan V. Bala, PhD; Keaven M. Anderson, PhD; Linda Davidson-Ray, BA; J. David Knight, MS; Catherine F. Cabot, MD; Eric J. Topol, MD; for the EPILOG Investigators 2923

*Supported in concept by an unrestricted gift from Merck & Co. Pfizer provides an unrestricted gift for subscriptions to *Circulation* for Cardiology Fellows in training.

CIRCULATION (ISSN 0009-7322) is published weekly except combined the first two weeks in January and the last two weeks in December by Lippincott Williams & Wilkins at 12107 Insurance Way, Hagerstown, MD 21740. Business offices are located at 227 East Washington Square, Philadelphia, PA 19106-3780. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. Individuals may subscribe for their personal use at the following rates: \$177 for members of an American Heart Association scientific council and \$236 for nonmembers; international: \$314 for members of an American Heart Association scientific council and \$418 for nonmembers. Periodicals postage paid at Hagerstown, MD, and additional mailing offices. POSTMASTER: Send address changes to CIRCULATION, American Heart Association, Lippincott Williams & Wilkins, 12107 Insurance Way, Hagerstown, MD 21740.

This material was copied
at the NLM and may be
subject to US Copyright Law.

Randomized Comparison of Primary Stenting and Provisional Balloon Angioplasty Guided by Flow Velocity Measurement <i>Patrick W. Serruys, MD; Bernard de Bruyne, MD; Stéphane Carlier, MD; José Eduardo Sousa, MD; Jan Piek, MD; Toshiya Muramatsu, MD; Chris Vrints, MD; Peter Probst, MD; Ricardo Seabra-Gomes, MD; Ian Simpson, MD; Vasilis Voudris, MD; Olivier Gurné, MD; Nico Pijls, MD; Jorge Belardi, MD; Gerrit-Anne van Es, PhD; Eric Boersma, PhD; Marie-Angèle Morel, MS; Ben van Hout, PhD; on behalf of the Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group</i>	2930
Randomized Comparison of Elective Stent Implantation and Coronary Balloon Angioplasty Guided by Online Quantitative Angiography and Intracoronary Doppler <i>Carlo Di Mario, MD, PhD; Jeffrey W. Moses, MD; Todd J. Anderson, MD, MRCP; Raoul Bonan, MD; Toshiya Muramatsu, MD; Abnash Chander Jain, MD; Josè Suarez de Lezo, MD; Seung Yun Cho, MD; Morton Kern, MD; Ian T. Meredith, MBBS, PhD; David Cohen, MD, MSc; Issam Moussa, MD; Antonio Colombo, MD; on behalf of the DESTINI Study Group (Doppler Endpoint STenting INTERNATIONAL Investigation)</i>	2938
Percutaneous Coronary Intervention in the Current Era Compared With 1985–1986: The National Heart, Lung, and Blood Institute Registries <i>David O. Williams, MD; Richard Holubkov, PhD; Wanlin Yeh, MS; Martial G. Bourassa, MD; Mahdi Al-Bassam, MD; Peter C. Block, MD; Paul Coady, MD; Howard Cohen, MD; Michael Cowley, MD; Gerald Dorros, MD; David Faxon, MD; David R. Holmes, MD; Alice Jacobs, MD; Sheryl F. Kelsey, PhD; Spencer B. King III, MD; Richard Myler, MD; James Slater, MD; Vladimir Stanek, MD; Helen A. Vlachos, MS; Katherine M. Detre, MD, DrPH; for the Coinvestigators</i>	2945
Enhanced Efficacy of Eptifibatid Administration in Patients With Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting <i>Steven P. Marso, MD; Deepak L. Bhatt, MD; Matthew T. Roe, MD; Penny L. Houghtaling, MS; Marino Labinaz, MD; Neal S. Kleiman, MD; Cornelius Dyke, MD; Maarten L. Simoons, MD; Robert M. Califf, MD; Robert A. Harrington, MD; Eric J. Topol, MD; for the PURSUIT Investigators</i>	2952
Immediate Changes of Collateral Function After Successful Recanalization of Chronic Total Coronary Occlusions <i>Gerald S. Werner, MD; Barbara M. Richartz, MD; Oliver Gastmann, MD; Markus Ferrari, MD; Hans R. Figulla, MD</i>	2959
Are Patients With Renal Failure Good Candidates for Percutaneous Coronary Revascularization in the New Device Era? <i>Mark H. Rubenstein, MD; Lari C. Harrell, MS; Boris V. Sheynberg, MD; Heribert Schunkert, MD; Hasan Bazari, MD; Igor F. Palacios, MD</i>	2966
Risks of Morbidity and Mortality in Dialysis Patients Undergoing Coronary Artery Bypass Surgery <i>Jean Y. Liu, MD; Nancy J.O. Birkmeyer, PhD; John H. Sanders, MD; Jeremy R. Morton, MD; Horace F. Henriques, MD; Stephen J. Lahey, MD; Richard W. Dow, MD; Christopher Maloney, MD; Anthony W. DiScipio, MD; Robert Clough, MD; Bruce J. Leavitt, MD; Gerald T. O'Connor, PhD, DSc; for the Northern New England Cardiovascular Disease Study Group</i>	2973
Evidence of <i>Trypanosoma cruzi</i> Infection (Chagas' Disease) Among Patients Undergoing Cardiac Surgery <i>David A. Leiby, PhD; Francisco J. Rentas, MS; Kenrad E. Nelson, MD; Veronica A. Stambolis, MA; Paul M. Ness, MD; Cheryl Parnis, RN; Hugh A. McAllister, Jr, MD; David H. Yawn, MD; Robert J. Stumpf, BS; Louis V. Kirchhoff, MD</i>	2978

Basic Science Reports

Effects of Estrogen Replacement on Infarct Size, Cardiac Remodeling, and the Endothelin System After Myocardial Infarction in Ovariectomized Rats <i>Paula J.W. Smith, PhD; Olga Ornatsky, PhD; Duncan J. Stewart, MD; Pierre Picard, PhD; Fayez Dawood, DVM; Wen-Hu Wen, MD; Peter P. Liu, MD; David J. Webb, MD; Juan Carlos Monge, MD</i>	2983
Antioxidant Effect of Estrogen on Cytomegalovirus-Induced Gene Expression in Coronary Artery Smooth Muscle Cells <i>Edith Speir, MS; Zu-Xi Yu, MD, PhD; Kazuyo Takeda, MD, PhD; Victor J. Ferrans, MD, PhD; Richard O. Cannon III, MD</i>	2990
Cyclic Nucleotide Phosphodiesterase Type 5 Activity Limits Blood Flow to Hypoperfused Myocardium During Exercise <i>Jay H. Traverse, MD; Ying Jie Chen, MD, PhD; Ruisheng Du, PhD; Robert J. Bache, MD</i>	2997

Trypanosoma cruzi–Infected Cardiomyocytes Produce Chemokines and Cytokines That Trigger Potent Nitric Oxide–Dependent Trypanocidal Activity <i>Fabiana S. Machado, MS; Gislaine A. Martins, PhD; Júlio C.S. Aliberti, PhD; Fabiola L.A.C. Mestriner, BS; Fernando Q. Cunha, PhD; João S. Silva, PhD</i>	3003
Endogenous Na,K Pump Ligands Are Differentially Regulated During Acute NaCl Loading of Dahl Rats <i>Olga V. Fedorova, PhD; Edward G. Lakatta, MD; Alexei Y. Bagrov, MD, PhD</i>	3009
Endotoxin-Induced Mortality Is Related to Increased Oxidative Stress and End-Organ Dysfunction, Not Refractory Hypotension, in Heme Oxygenase-1–Deficient Mice <i>Phillippe Wiesel, MD; Anand P. Patel, MS; Nicole DiFonzo, BS; Pooja B. Marria, BS; Chäng U. Sim, BS; Andrea Pellacani, MD, PhD; Koji Maemura, MD, PhD; Brian W. LeBlanc, BS; Kathryn Marino, BS; Claire M. Doerschuk, MD; Shaw-Fang Yet, PhD; Mu-En Lee, MD, PhD; Mark A. Perrella, MD</i>	3015

Images in Cardiovascular Medicine

Granulomatous Aortitis Presenting as an Acute Myocardial Infarction in Crohn’s Disease <i>Michael H. Goldman, MD; Bechara Akl, MD; Shayryar Mafi, MD; Lucia Pastore, MD</i>	3023
Annotated Table of Contents	A8
Classified Advertising	B2

The cover figure is from the article in this issue by Speir et al. Figure 1: SMCs were pretreated for 1 hour with indicated doses of E₂, 17α-E₂ (17a), 3-ME, or tamoxifen (TAM). Cells were then infected for 1 hour with CMV at 5 MOI, followed by addition of DCFH-DA fluorescent dye. Both stereoisomers of estradiol and tamoxifen, but not 3-ME, dose-dependently inhibited fluorescence, as determined by confocal laser microscopy. See page 2990.

Percutaneous Coronary Intervention in the Current Era Compared With 1985–1986

The National Heart, Lung, and Blood Institute Registries

David O. Williams, MD; Richard Holubkov, PhD; Wanlin Yeh, MS; Martial G. Bourassa, MD; Mahdi Al-Bassam, MD; Peter C. Block, MD; Paul Coady, MD; Howard Cohen, MD; Michael Cowley, MD; Gerald Dorros, MD; David Faxon, MD; David R. Holmes, MD; Alice Jacobs, MD; Sheryl F. Kelsey, PhD; Spencer B. King III, MD; Richard Myler, MD; James Slater, MD; Vladimir Stanek, MD; Helen A. Vlachos, MS; Katherine M. Detre, MD, DrPH; for the Coinvestigators

Background—Although refinements have occurred in coronary angioplasty over the past decade, little is known about whether these changes have affected outcomes.

Methods and Results—Baseline features and in-hospital and 1-year outcomes of 1559 consecutive patients in the 1997–1998 Dynamic Registry who were having first coronary intervention were compared with 2431 patients in the 1985–1986 National Heart, Lung, and Blood Institute Registry. Compared with patients in the 1985–1986 Registry, Dynamic Registry patients were older (mean age, 62 versus 58 years; $P<0.001$) and more often female (32.1% versus 25.5%; $P<0.001$). In the Dynamic Registry, procedures were more often performed for acute myocardial infarction (22.9% versus 9.9%; $P<0.001$) and treated lesions were more severe (84.5% versus 82.5% diameter reduction; $P<0.001$), thrombotic (22.1% versus 11.3%; $P<0.001$) or calcified (29.5% versus 10.8%; $P<0.001$). Stents were used in 70.5% of Dynamic Registry patients, whereas 1985–1986 patients received balloon angioplasty alone. Procedural success was higher in the Dynamic Registry (92.0% versus 81.8%; $P<0.001$) and the rate of in-hospital death, myocardial infarction, and emergency coronary bypass surgery combined was lower (4.9% versus 7.9%; $P=0.001$) than in the 1985–1986 Registry. The 1-year rate for CABG was lower in the Dynamic Registry (6.9% versus 12.6%; $P<0.001$).

Conclusions—Although Dynamic Registry patients had more unstable and complex coronary disease than those in the 1985–1986 Registry, their rate of procedural success was higher whereas rates of complications and subsequent CABG were lower. Results of percutaneous coronary intervention have improved substantially over the past decade. (*Circulation*. 2000;102:2945-2951.)

Key Words: angioplasty ■ coronary disease ■ arteries ■ balloon ■ stents

In 1979, the National Heart, Lung, and Blood Institute (NHLBI) established a voluntary registry to characterize coronary angioplasty, at the time an emerging technique of percutaneous coronary revascularization.¹ Patients were enrolled from 1977–1980 and subsequently from 1985–1986. These 2 registries provided the first comprehensive description of technical and clinical results, and in the mid-1980s identified that angioplasty had matured to the point that clinical trials were necessary to resolve the genuine dilemma as to potential comparability to CABG.

See p 2910

These trials, including Bypass Angioplasty Revascularization Investigation (BARI)² and EAST,³ found that in most patients with multivessel coronary artery disease (CAD), balloon angioplasty did not compromise survival and proved to save costs slightly relative to CABG but many patients who received PTCA required repeat revascularization. Since that time, new devices have been developed as potential adjuncts or replacements for the balloon catheter.⁴ Although

Received May 22, 2000; revision received July 20, 2000; accepted July 25, 2000.

From the Division of Cardiology (D.O.W.), Rhode Island Hospital, Brown University, Providence, RI; the Department of Epidemiology (R.H., W.Y., S.F.K., H.A.V., K.M.D.), University of Pittsburgh, Pittsburgh; Lankenau Hospital (P.C.), Philadelphia, Pa; Montreal Heart Institute (M.G.B.), Montreal, Quebec, Canada; Cardiovascular Medical Associates (M.A.-B.), Houston, Tex; Providence/St. Vincent Hospitals (P.C.B.), Portland, Ore; University of Pittsburgh Medical Center (H.C.), Pittsburgh, Pa; Medical College of Virginia (M.C.), Richmond, Va; Arizona Heart Institute (G.D.), Phoenix, Az; University of Southern California Medical Center (D.F.), Los Angeles, Calif; Mayo Clinic Foundation (D.R.H.), Rochester, NY; Boston University Medical Center (A.J.), Boston, Mass; Emory University Hospital (S.B.K. III), Atlanta, Ga; Seton Medical Center (R.M.), Daly City, Calif; St. Lukes/Roosevelt Hospital (J.S.), New York, NY; and Institute for Clinical and Experimental Medicine (V.S.), Prague, Czech Republic.

Additional coinvestigators are listed in the Appendix.

Correspondence to Katherine M. Detre, MD, DrPH, University of Pittsburgh/GSPH, 130 DeSoto St, 127 Parran Hall, Pittsburgh, PA 15261. E-mail Detre@cdc.gsp.h.pitt.edu

© 2000 American Heart Association, Inc.

Circulation is available at <http://www.circulationaha.org>

This material was copied
at the NLM on 05/05/05
Subject to US Copyright Law

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.